Alliancebernstein L.P. 13F: Cuts APGE Stake by $14M

Alliancebernstein Trims Position in Apogee Therapeutics

Alliancebernstein L.P. trimmed its stake in Apogee Therapeutics, Inc. (APGE) by 9.45%, selling 103,360 shares as of May 15, 2026. The firm now holds 990,297 shares valued at approximately $131.4 million. This reduction reflects a strategic adjustment in its portfolio, which may indicate a shift in market outlook or investment strategy.

What Changed in Alliancebernstein's Position

Alliancebernstein's reduction in its position marks a decrease from 1,093,657 shares to 990,297. The 103,360 shares sold represent a 9.45% decrease in their holdings. This move highlights how significant this stock is within the fund's overall portfolio.

Institutional Peers and Their Moves

No other institutional investors reported changes in their positions in Apogee Therapeutics during this period, indicating that Alliancebernstein's move stands out in the current landscape.

Stock Performance and Current Trading Context

Apogee Therapeutics shares are currently trading at $132.73, close to their 52-week high of $135.09. This performance suggests that the stock has been doing well, which may influence investor sentiment. The company's market cap is approximately $10.2 billion, and it has a forward P/E ratio of -26.0, indicating that it is not currently profitable.

Recent Earnings

Apogee Therapeutics is scheduled to report its next earnings on November 9, 2026. In its most recent earnings report, the company posted an EPS of -4.34 and has a net margin of 0.0%, reflecting challenges in profitability as it develops its biologic therapies for immunological and inflammatory diseases.

Insider Buying and Selling at Apogee Therapeutics, Inc.

On June 22, 2026, Chief Medical Officer Carl Dambkowski sold 26,400 shares at an average price of $132.60, totaling about $3.5 million. This transaction was part of a planned selling strategy under Rule 10b5-1, indicating a structured approach to managing his holdings.

Analysts Set New Price Targets

Several analysts have recently downgraded their ratings for Apogee Therapeutics. On August 13, 2026, Truist Securities maintained a 'Hold' rating with a price target of $135. Other firms such as BTIG and Stifel also downgraded the stock to 'Neutral' or 'Hold' in late June, reflecting a consensus view that is cautious about the stock's near-term prospects.

What Apogee Therapeutics, Inc. Does

Apogee Therapeutics, Inc. focuses on developing biologic therapies for patients with immunological and inflammatory diseases. With a strong pipeline of monoclonal antibodies targeting various conditions, the company's future performance will depend significantly on its ability to navigate the biotech landscape and achieve profitability.

What's Ahead for Apogee Therapeutics, Inc.

Investors will be watching closely for Apogee's next earnings report on November 9, 2026, as well as any further developments in its product pipeline. The recent 13F filing from Alliancebernstein provides a snapshot of past positions, which may not reflect current strategies or sentiment toward Apogee's future potential.